The phase 1 trial, EGRET, is ongoing and aims to evaluate AZD9592 monotherapy and AZD9592 plus osimertinib in metastatic NSCLC with EGFRm (sensitizing L858R mutation or exon19 deletion) and EGFR WT64. Here, EGFR is linked to non-small cell lung carcinoma.